Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
enGene Holdings Inc. is a biotech company developing genetic medicines using its proprietary DDX platform. Its lead candidate, detalimogene, aims to treat bladder cancer, particularly BCG-unresponsive NMIBC with CIS. The company focuses on localized gene delivery, immune activation, and scalable manufacturing. It targets unmet medical needs in oncology, with plans for regulatory approval and independent commercialization in the U.S. market.
This description was generated via AI from an annual report. Updated about 1 year ago.